Amo Pharma Limited
Clinical trials sponsored by Amo Pharma Limited, explained in plain language.
-
New drug trial aims to ease symptoms of rare muscle disease in kids
Disease control CompletedThis study tested a drug called tideglusib against a placebo in 56 children aged 6 to 16 with congenital myotonic dystrophy, a rare genetic muscle condition. The goal was to see if tideglusib could reduce symptom severity and improve overall function. The trial was completed, but…
Phase: PHASE2, PHASE3 • Sponsor: AMO Pharma Limited • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
Experimental drug tideglusib tested for rare muscle disease
Disease control CompletedThis study tested a drug called tideglusib in 16 adolescents and adults with a rare muscle disease called myotonic dystrophy type 1. The goal was to see if the drug is safe and if it helps with symptoms. Participants took either 400 mg or 1000 mg of tideglusib daily, and research…
Phase: PHASE2 • Sponsor: AMO Pharma Limited • Aim: Disease control
Last updated May 18, 2026 11:58 UTC